To determine the relationship between gastroesophageal reflux disease (GORD) and its treatment and interstitial lung disease in patients with systemic sclerosis (SSc). SSc patients from the Australian Scleroderma Cohort Study (ASCS) were included. GORD was defined as self-reported GORD symptoms, therapy with a proton pump inhibitor (PPI) or histamine 2 receptor antagonist (H2RA) and/or the presence of reflux oesophagitis diagnosed endoscopically. The impact of GORD and its treatment on ILD features (including severity and time to ILD development) and survival was evaluated. GORD was a common manifestation affecting 1539/1632 (94%) of SSc patients. GORD affected 450/469 (96%) of those with SSc-ILD cohort. In SSc-ILD, there was no relationship between the presence of GORD or its treatment and time to ILD development or ILD severity. However, GORD treatment was associated with improved survival in those with ILD (p = 0.002). Combination therapy with both a PPI and a H2RA was associated with a greater survival benefit than single agent therapy with PPI alone (HR 0.3 vs 0.5 p < 0.050 respectively). GORD is a common SSc disease manifestation. While the presence or treatment of GORD does not influence the development or severity of ILD, aggressive GORD treatment, in particular with a combination of PPI and H2RA, is associated with improved survival in those with SSc-ILD.

中文翻译：

---

胃食管反流病及其治疗对间质性肺病结局的影响


确定胃食管反流病（GORD）及其治疗与系统性硬化症（SSc）患者间质性肺疾病之间的关系。来自澳大利亚硬皮病队列研究 (ASCS) 的 SSc 患者被纳入其中。 GORD 被定义为自我报告的 GORD 症状、使用质子泵抑制剂 (PPI) 或组胺 2 受体拮抗剂 (H2RA) 治疗和/或内镜诊断存在反流性食管炎。评估了 GORD 及其治疗对 ILD 特征（包括严重程度和 ILD 发展时间）和生存的影响。 GORD 是影响 1539/1632 (94%) 的 SSc 患者的常见表现。 GORD 影响了 450/469 (96%) 的 SSc-ILD 队列患者。在 SSc-ILD 中，GORD 的存在或其治疗与 ILD 发展时间或 ILD 严重程度之间没有关系。然而，GORD 治疗与 ILD 患者的生存率改善相关（p = 0.002）。 PPI 和 H2RA 联合治疗比单独使用 PPI 的单药治疗具有更大的生存获益（HR 分别为 0.3 vs 0.5 p<0.050）。 GORD 是一种常见的 SSc 疾病表现。虽然 GORD 的存在或治疗不会影响 ILD 的发展或严重程度，但积极的 GORD 治疗，尤其是 PPI 和 H2RA 联合治疗，可改善 SSc-ILD 患者的生存率。